All In Biotech

Drug Trial Radar · NCT06453902

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

A Single-arm, Open-label, Multi-center Phase II Study Evaluating Efficacy and Safety of TGRX-678 in CML-AP Patients Relapsed or Refractory From 3rd-generation TKI Treatment

Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 15, 2024

Primary completion

Jun 30, 2026

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Shenzhen TargetRx Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Peking University People's Hospital; Henan Cancer Hospital; Nanfang Hospital, Southern Medical University; The First Affiliated Hospital of Soochow University; Chinese Academy of Medical Sciences; First Affiliated Hospital of Zhejiang University; Shenzhen Second People's Hospital; Ruijin Hospital; Shengjing Hospital; Huazhong University of Science and Technology
First posted
Jun 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment

Conditions

  • Chronic Myeloid Leukemia
  • Accelerated Phase CML

Interventions

  • TGRX-678Drug

    All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Hematologic Response (MaHR)Time frame: At screening, on Day 1 of every treatment cycle (each cycle is 28 days) and at end of treatment; average of study duration is 3.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.